Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CID-375076
- Development stage
- Preclinical
- Lead developer
- AIIMS Rishikesh
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CID-375076 is a small-molecule oxazolidine derivative identified as a potent inhibitor of the Hepatitis C virus (HCV) NS3 protease catalytic domain. Discovered through structure-based virtual screening and flexible docking of oxazolidine derivatives, CID-375076 exhibits strong binding affinity within the active site of the NS3 protease, forming critical hydrogen bonds and hydrophobic contacts with key substrate-binding residues and the catalytic triad (His57, Asp81, and Ser139). Preclinical ADMET profiling predicts high oral bioavailability, non-hepatotoxicity, and a lack of CYP450 inhibition, supporting its potential as a drug-like lead compound for the treatment of HCV infection.
02
Targets
NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)
Beyond the preview
Go deeper on CID-375076.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CID-375076.